Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Immatics N.V.NASDAQ: IMTX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 134.64M shares rose 10.8% year over year, behind the +13.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 6.8% from the prior quarter. Over 3 fiscal years it compounded at +21.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.8% toward the trailing-twelve-month pace of +13.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
134.64M+6.8% QoQ
Last fiscal yearDec 2025
122.35M+14.6% YoY
LTMMar 2026
125.95M+13.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.8%——
1 year+14.6%——
3-year CAGR+21.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
122.35M EUR
Year-over-year change
+14.6%
4-year CAGR
+18.1%

Weighted Avg Shares (Diluted) vs competitors

How IMTX compares with its peers on the latest reported figures

  • IMTX's LTM Mar 2026 weighted avg shares (diluted) of 125.95M shares is the 5th highest of the 11 companies compared; the peer median is 81.26M shares.
  • Its year-over-year change of +13.3% is the 4th highest of 11, against a peer median of +8.4%.
  • Over three fiscal years its annual growth of +21.1% compares with a peer median of +14.9%.
IMTX Competitors Peer median
Weighted Avg Shares (Diluted) for IMTX and competitors
Company Period LTM YoY 3-year CAGR
BNTXBioNTech SELTM Jun 2026247.64M +2.5%-1.1%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
LEGNLegend Biotech CorporationLTM Sep 2026189.27M +2.9%+5.0%
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
IMTXImmatics N.V.LTM Mar 2026125.95M +13.3%+21.1%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
JANXJanux Therapeutics, Inc.LTM Mar 202662.14M +9.2%+14.3%
IMCRImmunocore Holdings plcLTM Mar 202650.99M -0.4%+3.3%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
ATRAAtara Biotherapeutics, Inc.LTM Mar 202613.17M +49.9%+46.1%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +60.9%+63.6%
Peer median (excluding IMTX) 81.26M+8.4%+14.9%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.76M172.83M54M155.84M48.27M
Cost of Revenue87.57M106.78M118.66M00
Gross Profit(52.81M)66.05M(64.67M)155.84M48.27M
Gross Margin-151.9%38.2%-119.8%100.0%100.0%
Research & Development87.57M106.78M118.66M148.08M183.83M
Selling, General & Admin33.81M36.12M38.2M46.45M51.18M
Operating Expenses121.05M142.88M155.72M194.45M230.28M
Depreciation & Amortization5.47M6.84M7.23M12.23M12.4M
EBITDA(87.3M)50.04M(88.93M)34.46M(185.09M)
EBITDA Margin-251.1%29.0%-164.7%22.1%-383.5%
Operating Income(86.29M)29.95M(101.73M)(38.62M)(182.02M)
Operating Margin-248.2%17.3%-188.4%-24.8%-377.1%
Interest Income133K2.48M13.85M25M17.18M
Interest Expense566K1.04M831K886K946K
Other Income / Expenses(7.04M)12.08M4.73M59.96M(16.42M)
Income Before Tax(93.34M)42.04M(96.99M)21.35M(198.44M)
Pre-Tax Margin-268.5%24.3%-179.6%13.7%-411.1%
Income Tax Expense04.55M06.13M(1.99M)
Net Income(95.06M)37.51M(96.99M)15.22M(196.45M)
Net Margin-273.5%21.7%-179.6%9.8%-407.0%
EPS (Basic)(1.51)0.55(1.20)0.14(1.54)
EPS (Diluted)(1.51)0.54(1.20)0.14(1.54)
Weighted Avg Shares62.91M67.22M80.55M108.7M122.35M
Weighted Avg Shares (Diluted)62.91M68.82M80.55M106.8M122.35M

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.